A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Vorinostat (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 09 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2017.
- 21 Apr 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.